Cannara Financial Statements From 2010 to 2024

Stocks Canada . 
Stock . Cannara Biotech
LOVE Stock  CAD 0.78  0.08  11.43%   
Cannara Biotech financial statements provide useful quarterly and yearly information to potential Cannara Biotech investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cannara Biotech financial statements helps investors assess Cannara Biotech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cannara Biotech's valuation are summarized below:
Gross Profit
17.3 M
Profit Margin
0.0693
Market Capitalization
70.2 M
Enterprise Value Revenue
1.3691
Revenue
76.7 M
There are over one hundred nineteen available fundamental signals for Cannara Biotech, which can be analyzed over time and compared to other ratios. All traders should should validate Cannara Biotech's prevailing fundamental trends against the trends from 2010 to 2024 to make sure the company is sustainable. Market Cap is likely to climb to about 128.1 M in 2024. Enterprise Value is likely to climb to about 143.2 M in 2024

Cannara Biotech Total Revenue

69.14 Million

Check Cannara Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cannara Biotech's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Interest Income of 181 K or Interest Expense of 4.7 M, as well as many indicators such as Price To Sales Ratio of 0.71, Dividend Yield of 0.0 or PTB Ratio of 0.66. Cannara financial statements analysis is a perfect complement when working with Cannara Biotech Valuation or Volatility modules.
  
This module can also supplement various Cannara Biotech Technical models . Check out the analysis of Cannara Biotech Correlation against competitors.

Cannara Biotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets93.7 M162.8 M64.6 M
Slightly volatile
Total Current Liabilities25.6 M24.4 M7.2 M
Slightly volatile
Total Stockholder Equity57 M91.7 M37.5 M
Slightly volatile
Net Tangible Assets50.7 M76.7 M35.2 M
Slightly volatile
Accounts Payable16.8 M16 M5.2 M
Slightly volatile
Cash3.7 M3.8 M11.3 M
Slightly volatile
Non Current Assets Total63.7 M103.3 M41.5 M
Slightly volatile
Other Assets808 K1.1 M1.3 M
Slightly volatile
Long Term Debt26.2 M45.6 M20.2 M
Slightly volatile
Net Receivables12.8 M12.2 M3.5 M
Slightly volatile
Common Stock Shares Outstanding77.2 M81.3 M600.3 M
Slightly volatile
Non Current Liabilities Total27.1 M46.7 M20.8 M
Slightly volatile
Capital Lease Obligations150.5 K158.4 K443.8 K
Slightly volatile
Total Liabilities36.2 M71 M26.9 M
Slightly volatile
Net Invested Capital84.8 M144.2 M58.8 M
Slightly volatile
Total Current Assets30 M59.5 M23.2 M
Slightly volatile
Capital Stock70.5 M102.1 M44.5 M
Slightly volatile
Net Working Capital20.9 M35.1 M17.1 M
Slightly volatile
Common Stock65.4 M95.8 M44.4 M
Slightly volatile
Property Plant Equipment55.4 M95.9 M38.9 M
Slightly volatile
Other Current Liabilities69.6 K40.7 K146.1 K
Slightly volatile
Inventory40.8 M38.8 M9.6 M
Slightly volatile
Other Current Assets3 M3.5 M1.4 M
Slightly volatile
Intangible Assets177.3 K146.1 K233.5 K
Slightly volatile
Other Liabilities772.3 K939 K659.8 K
Slightly volatile
Property Plant And Equipment Net79.7 M102.9 M57.7 M
Slightly volatile
Net Debt25.9 M47.5 M13.9 M
Slightly volatile
Property Plant And Equipment Gross88.7 M119.2 M63.4 M
Slightly volatile
Short and Long Term Debt7.2 M6.9 M1.7 M
Slightly volatile
Non Current Liabilities Other60 K67.5 K73.5 K
Slightly volatile

Cannara Biotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income181 K215.6 K129.6 K
Slightly volatile
Selling General Administrative9.7 M15.5 M6.1 M
Slightly volatile
Total Revenue69.1 M65.8 M16.8 M
Slightly volatile
Gross Profit32.9 M31.3 M8.2 M
Slightly volatile
Cost Of Revenue36.3 M34.5 M8.7 M
Slightly volatile
Total Operating Expenses54.6 M52 M16.2 M
Slightly volatile
Reconciled Depreciation6 M5.7 M1.8 M
Slightly volatile
Research Development1.4 M927.8 K2.2 M
Slightly volatile

Cannara Biotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation6 M5.7 M1.9 M
Slightly volatile
Capital Expenditures15.4 M8.9 M22.4 M
Slightly volatile
End Period Cash Flow3.7 M3.8 M11.3 M
Slightly volatile
Change To Liabilities2 M2.8 M2 M
Pretty Stable
Stock Based Compensation865 K1.6 M1.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.710.7492267
Slightly volatile
PTB Ratio0.660.69648.3467
Slightly volatile
Days Sales Outstanding55.358.2092298
Slightly volatile
Book Value Per Share0.560.97650.4649
Slightly volatile
Average Payables5.1 M9.4 M4.4 M
Slightly volatile
Stock Based Compensation To Revenue0.0230.02420.2686
Slightly volatile
Capex To Depreciation1.121.175776.9942
Slightly volatile
PB Ratio0.660.69648.3467
Slightly volatile
EV To Sales1.21.2594267
Slightly volatile
Payables Turnover5.545.27951.3352
Slightly volatile
Sales General And Administrative To Revenue0.150.15872.5867
Slightly volatile
Research And Ddevelopement To Revenue0.0130.01370.6925
Slightly volatile
Capex To Revenue0.08680.091419.5956
Slightly volatile
Cash Per Share0.06980.07350.1605
Slightly volatile
Days Payables Outstanding65.6869.13541.2 K
Slightly volatile
Intangibles To Total Assets0.00390.00340.0038
Slightly volatile
Current Ratio4.922.49887.8209
Slightly volatile
Tangible Book Value Per Share0.560.97650.4644
Slightly volatile
Receivables Turnover3.786.27052.804
Slightly volatile
Graham Number0.881.25320.7621
Slightly volatile
Shareholders Equity Per Share0.560.97650.4622
Slightly volatile
Debt To Equity0.410.54210.6626
Slightly volatile
Capex Per Share0.07880.08290.2015
Slightly volatile
Average Receivables1.3 M1.5 M1.6 M
Slightly volatile
Revenue Per Share0.950.90760.2164
Slightly volatile
Interest Debt Per Share0.30.57740.2783
Slightly volatile
Debt To Assets0.240.30820.3568
Slightly volatile
Operating Cycle312340206
Slightly volatile
Price Book Value Ratio0.660.69648.3467
Slightly volatile
Days Of Payables Outstanding65.6869.13541.2 K
Slightly volatile
Company Equity Multiplier1.341.75921.7817
Slightly volatile
Long Term Debt To Capitalization0.340.30420.383
Slightly volatile
Total Debt To Capitalization0.260.35150.3841
Slightly volatile
Debt Equity Ratio0.410.54210.6626
Slightly volatile
Quick Ratio0.961.01487.2946
Slightly volatile
Net Income Per E B T1.071.291.2331
Slightly volatile
Cash Ratio0.230.24526.6
Slightly volatile
Days Of Sales Outstanding55.358.2092298
Slightly volatile
Price To Book Ratio0.660.69648.3467
Slightly volatile
Fixed Asset Turnover1.010.96130.2422
Slightly volatile
Debt Ratio0.240.30820.3568
Slightly volatile
Price Sales Ratio0.710.7492267
Slightly volatile
Asset Turnover0.550.52840.1434
Slightly volatile
Gross Profit Margin0.560.36440.4478
Slightly volatile
Price Fair Value0.660.69648.3467
Slightly volatile

Cannara Biotech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap128.1 M70.4 M158.6 M
Slightly volatile
Enterprise Value143.2 M118.4 M168.3 M
Slightly volatile

About Cannara Biotech Financial Statements

Cannara Biotech investors use historical fundamental indicators, such as Cannara Biotech's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cannara Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue65.8 M69.1 M
Cost Of Revenue34.5 M36.3 M
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 0.16  0.15 
Research And Ddevelopement To Revenue 0.01  0.01 
Capex To Revenue 0.09  0.09 
Revenue Per Share 0.91  0.95 
Ebit Per Revenue 0.12  0.13 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Cannara Stock Analysis

When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY